Stock Market Reviews

NVO (Novo Nordisk A/S) News

Get the latest news, insights, and market updates on NVO (Novo Nordisk A/S). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
  European equities traded in the US as American depositary receipts were tracking lower late Monday m
  Dec 29, 2025 - $NVO
• European Stocks Close Little Changed in Monday Trading; Novo Nordisk Slashes Wegovy Prices in China
  The European stock markets closed little changed in Monday trading as The Stoxx Europe gained 0.11%,
  Dec 29, 2025 - $NVO
• Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Investors Await Fed Minutes
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.3% and the actively tr
  Dec 29, 2025 - $NVO
• This Beaten-Down Stock Just Jumped By 8%. Time to Buy?
  Is this the start of a sustained run for the Danish drugmaker?
  Dec 29, 2025 - $NVO
• The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA.
  Other drugmakers seem to be too far behind to disrupt this duopoly, at least for now.
  Dec 29, 2025 - $NVO
• Joel Habener, Whose Research Helped Develop Weight-Loss Drugs, Dies at 88
  Joel F. Habener, a Harvard University academic whose research paved the way for revolutionary weight-loss drugs Ozempic, Mounjaro and others, which analysts forecast will be the biggest blockbusters in pharmaceutical history, died Sunday in Newton, Mass. He was 88. Eileen Martin, a friend of Habener’s, said he died peacefully at home. Habener led research that discovered a hormone dubbed GLP-1.
  Dec 29, 2025 - $NVO
• Novo Nordisk just pulled off something nobody saw coming
  Novo Nordisk just got a big win from the FDA, and it could change the weight-loss medicine industry again. Novo has a new weapon in its obesity portfolio with the once-daily Wegovy tablet, which is the first oral GLP-1 medication approved in the U.S. for weight loss. This comes at a time when ...
  Dec 28, 2025 - $NVO
• 3 Drug Stocks to Buy at a Discount
  The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.
  Dec 27, 2025 - $NVO
• Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access
  US price cuts, Medicare expansion, and new oral GLP-1 approvals reshape the competitive outlook for weight-loss drugs.
  Dec 26, 2025 - $NVO
• Bear of the Day: Novo Nordisk (NVO)
  Competition is fierce in the weight-loss drug industry and analysts are signaling a possible peak in growth
  Dec 26, 2025 - $NVO